Sort
15,273 grants matching “antimicrobial resistance”
Resolving the bottleneck in antibiotic discovery
$1,807,186Kim Lewis · Northeastern University · P01 · FY2020 · AI
Systems Biology Approach to Redefine Susceptibility Testing and Treatment of MDR Pathogens in the Context of Host Immunity
$1,806,219Bernhard O Palsson · University Of California, San Diego · U01 · FY2020 · AI
Starve and Kill: Engineered Antigens Targeting Nutrient Acquisition Pathways Essential for Gonococcal Infection and Disease
$1,806,071Cynthia Nau Cornelissen · Georgia State University · U19 · FY2022 · AI
Developing Novel Antibiotics Against Yersinia pestis
$1,805,783Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2008 · AI
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CF
$1,805,147Christopher Hooper Goss · University Of Washington · UM1 · FY2016 · HL
Immunotherapy to prevent drug-resistant tuberculosis
$1,804,739Rhea N Coler · Seattle Children'S Hospital · R01 · FY2020 · AI
Developing Novel Antibiotics Against Yersinia pestis
$1,795,670Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2006 · AI
Phenotypically amplified assay for rapid, automated determination of beta-lactam susceptibility
$1,795,199Ian M White · Univ Of Maryland, College Park · R01 · FY2025 · AI
Structural characterization of OM proteins from Gram-negative pathogens
$1,790,153Susan Buchanan · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2016 · DK
TASK C34: PILOT INFECTION MODEL IN PIG-TAILED MACAQUES: ASSESSMENT OF NEISSERIA GONORRHEA (GC) AND CHLAMYDIA TRACHOMATIS (CT) CO-INFECTION
$1,781,563Dorothy Patton · Bioqual, Inc. · N01 · FY2017 · AI
Decreasing Bioburden to Reduce Healthcare-Associated Infections and Readmissions
$1,780,817Susan S Huang · University Of California-Irvine · UH3 · FY2014 · AI
Collateral Consequences of Enabler Genotypes in Antibiotic Treatment Failure.
$1,774,417Jason W. Rosch · Boston Children'S Hospital · U19 · FY2024 · AI
Discovery of Natural Products and Natural Product-Like Inhibitors
$1,773,434Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2020 · DK
Discovery of Natural Products and Natural Product-Like Inhibitors
$1,773,434Carole Bewley · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK
University of Cape Town Clinical Trials Unit (UCTCTU)
$1,764,076Linda-Gail Bekker · University Of Cape Town · UM1 · FY2018 · AI
Approaches To Immunological Intervention In Schistosomiasis
$1,761,002Thomas Wynn · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Systems Biology of Microbiome-mediated Resilience to Antibiotic-resistant Pathogens
$1,755,886Joao Xavier · Sloan-Kettering Inst Can Research · U01 · FY2020 · AI
University of Cape Town Clinical Trials Unit (UCTCTU)
$1,749,653Linda-Gail Bekker · University Of Cape Town · UM1 · FY2017 · AI
Discovery, Design, and Development of Phosphonic Acid Antibiotics
$1,749,052William W. Metcalf · University Of Illinois At Urbana-Champaign · P01 · FY2012 · GM
Autophagy-Inducting Peptides and Target Identification for Treatment of Viruses
$1,748,997Beth C Levine · Washington University · U19 · FY2017 · AI
Resolving the bottleneck in antibiotic discovery
$1,748,006Kim Lewis · Northeastern University · P01 · FY2017 · AI
Antimicrobial Oligomers for BioDefense and Emerging Food Borne Infectious Disease
$1,745,299Gregory N. Tew · University Of Massachusetts Amherst · U01 · FY2011 · AI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES
$1,743,108Anne Kathleen Radcliff · Cubrc, Inc. · N01 · FY2015 · AI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES
$1,743,107Anne Kathleen Radcliff · Cubrc, Inc. · N01 · FY2015 · AI
Resolving the bottleneck in antibiotic discovery
$1,738,405Kim Lewis · Northeastern University · P01 · FY2018 · AI